[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582589":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":24,"locations":30,"responsibleParty":53,"collaborators":23,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":23,"enrollmentInfo":67,"targetDuration":23,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":32,"whyStopped":23,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients diagnosied with neuromyelitis optica spectrum disorder and MOG antibodies associated diseas","Patients will undergo a peripheral venous blood draw of approximately 5 ml (collected in EDTA) during routine blood tests for DNA extraction and genetic analysis, limited to the reserach of FCG3A polymorphisms. The results obtained will be compared with a control-group composed by patients diagnosed with Multiple sclerosis.",[12],"Procedure: Blood draw for the laboratory assessment",{"label":14,"type":6,"description":15,"interventionNames":16},"Patients diagnosied with Multiple Sclerosis","Patients will undergo a peripheral venous blood draw of approximately 5 ml (collected in EDTA) during routine blood tests for DNA extraction and genetic analysis, limited to the reserach of FCG3A polymorphisms. This is a comparison group.",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Blood draw for the laboratory assessment","Blood draw of approximately 5 ml of peripheral venous blood (collected in EDTA) will be collected for DNA extraction and genetic analysis limited to the research of FCG3A polymorphisms",[14,9],null,[25],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Massimiliano Mirabella, Neurology Associate Professor","CONTACT","0630155390","massimiliano.mirabella@policlinicogemelli.it",[31],{"facility":5,"status":32,"city":33,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Roma","00168","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],11.10642,44.99364,{"lat":41,"lon":40},[44,46,49,51],{"name":45,"role":27,"phone":28,"phoneExt":23,"email":29},"Massimiliano Mirabella",{"name":47,"role":48,"phone":23,"phoneExt":23,"email":23},"Alessandra Cicia, Neurologist","SUB_INVESTIGATOR",{"name":50,"role":48,"phone":23,"phoneExt":23,"email":23},"Assunta Bianco, Neurologist",{"name":52,"role":48,"phone":23,"phoneExt":23,"email":23},"Matteo Lucchini, Neurologist",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Mirabella Massimiliano","Associate Professor","100582589","frequency-of-fcgr3a-gene-polymorphisms-in-patients-with-neuromyelitis-optica-spectrum-disorders-anti-oligodendrocyte-myelin-protein-antibody-disease-and-multiple-sclerosis-100582589",false,"NCT06865274","Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.","Multicenter Prospective Interventional Study to Evaluate the Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody Disease, and Multiple Sclerosis.","PoGe","Inclusion Criteria:\n\n* Adult patients diagnosed with MS, NMOSD, or MOGAD receiving care at participating centers\n* Patients aged ≥ 18 years\n* Ability to understand and sign informed consent\n\nExclusion Criteria:\n\n* Individuals under 18 years of age\n* Inability to provide informed consent","ALL","18 Years",{"count":68,"type":69},50,"ESTIMATED","INTERVENTIONAL",[72],"NA","The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in a a comparison group of patients affected with Multiple Sclerosis (MS).\n\nThe study will involve adult patients diagnosed with MS, NMOSD, or MOGAD, followed at various clinical centers in the Lazio region.\n\nPatients from the participating clinical centers will be selected, and their medical records will be analyzed to collect clinical and neuroimaging data. The data will include demographic information such as age, sex and body mass index and clinical information such as age at disease onset, disease duration, antibody status (AQP4+\u002F- and MOG+\u002F-), disease-modifying therapies, as well as MRI data and the Expanded Disability Status Scale (EDSS) score.\n\nEach patient included in the study will undergo a single blood draw of approximately 5 ml of peripheral venous blood during routine blood tests, which will be used for DNA extraction and polimorphysm analysis. Demographic and clinical differences between patients with NMOSD and MOGAD, with and without the polymorphism, will be assessed and compared with the group of patients with MS.",[75,76,77],"Neuromyelitis Optica Spectrum Disorders","MOGAD","Multiple Sclerosis",[79,76,80,81,82],"NMOSD","MS","polymorphysm","FCG3A","2025-03-05",{"date":85,"type":86},"2025-03-07","ACTUAL",{"date":88,"type":86},"2025-02-20",{"date":90,"type":69},"2027-02-28",{"name":5,"class":6},1]